MolPort expansion enables more efficient compound and reagent sourcing in US
E-commerce platform serves scientists by providing a wide selection of compounds from trusted worldwide suppliers for easy search, convenient ordering and hassle-free delivery.
MolPort, a dedicated full-service e-commerce platform with extensive expertise in compound sourcing, has expanded into the US with the opening of MolPort Inc. This new business unit will further streamline the compound ordering process for its many US customers, who will benefit from faster, more efficient ordering and payment procedures, as well as improved customs navigations.
MolPort combines specialized expertise and innovative software tools for compound sourcing with an extensive database of over 7.6 million stock compounds from more than 60 industry-leading suppliers. In doing so, MolPort enables scientists to focus on their research and not on the often lengthy and complex procurement process.
For over a decade, MolPort’s core expertise in compound sourcing has been helping scientists accelerate drug discovery and compound screening programmes. The company provides one of the most trusted and reliable selections of screening compounds and building blocks to benefit computational and medicinal chemists, among others. By combining natural compounds and other small molecules and building blocks from multiple suppliers, scientists are able to place a single order that includes entities from across different catalogues to generate the best library for their requirements.
MolPort consolidates its commercially available compound database by integrating catalogues from multiple suppliers to produce a single searchable e-commerce platform. It is simple and intuitive to use and is updated and synchronized with supplier inventories on a daily basis. The database can be accessed through an advanced and powerful structure search or list search. Ordering can take place via the online e-shop, or integrated with a company’s procurement system. MolPort’s expert customer service team is easy to reach and fully equipped to use and advise on existing database tools to help build customer libraries, as well as create custom solutions for their clients. The expertise and knowledge of the MolPort team means that they are well-placed to consult with customers to precisely understand their requirements, build personalized libraries, and provide detailed product-specific information and integration solutions.
Dr Nicholas Malmquist, Institut Pasteur, commented: “I found MolPort when I was looking to re-source screening hit compounds. The MolPort website is very intuitive and makes it easy to search for exactly what you need or even similar related compounds. The ordering process is very easy and they take care of sourcing and shipping from multiple suppliers. MolPort is my first stop now for sourcing small molecules.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.